
Immutep Investor Relations Material
Latest events

AGM 2024
Immutep

Corporate Presentation
1 Jun, 2025

Q3 2025
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immutep Limited
Access all reports
Immutep Limited is a clinical-stage biotechnology company, recognized for its pioneering work in developing novel immunotherapy for cancer and autoimmune diseases. The company's research and development efforts are centered on Lymphocyte Activation Gene-3 (LAG-3), a crucial cell surface molecule that plays a significant role in regulating the immune system. Immutep's portfolio includes a range of innovative immunotherapies designed to either stimulate or suppress the immune system to combat cancer or autoimmune diseases. The company is headquartered in Sydney, Australia, and its shares are listed on the Nasdaq.
Key slides for Immutep Limited


AGM 2024
Immutep Limited


Corporate Presentation
Immutep Limited
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
IMM
Country
🇦🇺 Australia